Investigation of Copy Number Variations and Genetic Variants in POI (POI)

Insight Into the Genomics of Idiopathic Premature Ovarian Insufficiency

Primary ovarian insufficiency (POI), also known as premature ovarian failure, is an ovarian defect characterized by the premature (before the age of 40 years) depletion of ovarian follicles. POI affects about 1% of women, reaching 30% in some familial cases.

This heterogeneous disorder is characterized by progressive cessation of the ovarian function with temporary or intermittent amenorrhea associated with elevated serum FSH concentration and low AMH dosage. Low serum AMH dosage is able to detect a diminished ovarian pool occurring before the onset of FSH elevation and the ultimate deficiency leading to amenorrhea.

POI causes infertility and a poor ovarian response in IVF stimulations, and it has important health consequences for affected patients, including psychological distress, infertility, osteoporosis, autoimmune disorders, ischaemic heart disease.

Although the cause of POI remains unknown in about 80% of the cases, several mechanisms have been proposed to explain ovarian dysfunction. Currently, a wide spectrum of causes has been linked to POI, including genetic, autoimmune, infectious, or iatrogenic ones.

Genetic causes are highly heterogeneous and might explain at least some of the sporadic idiopathic cases, which comprise 50-90% of cases. Ten to fifteen percent of cases are X-linked abnormalities, mainly Turner Syndrome (45,X) or X structural abnormalities such as X deletions, X inversions, isochromosomes or X-autosome translocations. Also fragile X mental retardation 1 (FMR1) gene permutation (defined as having 55 to 200 CGG repeats in the 5' untranslated region of the gene) is another frequent genetic etiology.

Irrespectively, the majority of cases remains idiopathic, and identifying precise causative genes for POI has been challenging.

Study Overview

• Status: Recruiting
• Conditions: Primary Ovarian Insufficiency

Detailed Description

Although in the last decades an increasing number of aberrant genes involved in POI were identified, currently only a minority of affected women can be explained at gene level. Elucidating the biology of the premature declining ovarian function is paramount to develop better testing and treatment strategies for affected women in the future.

Importantly, two clinical features remain unexplained: i) the overall sporadic nature of POI, and ii) observations of patients harboring the identical mutation yet developing POI either early in life (puberty) or later (< 40 years old). Therefore, the investigators postulate that defects affecting more than one gene might explain this variability. Based on investigators' preliminary data and literature reports, it is likely that a synergistic effect of several variant/gene abnormalities may underlie the idiopathic POI phenotype.

The investigators hypothesize that different genome-wide strategies (namely, high resolution array-CGH and WES) may discover genetic variants without the limitation of a single candidate or a panel of candidates, and thus are more promising for explanation of the genetic heterogeneity of POI and elucidating the pathogenic mechanisms.

• Study Type: Observational
• Enrollment (Anticipated): 100

Contacts and Locations

• Study Contact: Name: Paola Scaruffi, PhD; Email: paola.scaruffi@hsanmartino.it

Study Locations

• Italy
  • Genova, Italy
    • Recruiting
    • UOS Fisiopatologia della Riuproduzione Umana
    • Contact: Paola Scaruffi, PhD; Email: paola.scaruffi@hsanmartino.it
    • Sub-Investigator: Sara Stigliani, PhD
    • Sub-Investigator: Claudia Massarotti, MD
    • Sub-Investigator: Paola Anserini, MD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 15 years to 38 years (Child, Adult)
• Accepts Healthy Volunteers: N/A
• Genders Eligible for Study: Female

• Sampling Method: Non-Probability Sample

Study Population

Idiopathic, sporadic and familial POI cases.

Description

Inclusion Criteria:

• age at diagnosis <38 years;
• a normal 46,XX karyotype (no FRM1 premutation);

• at least one marker of ovarian reserve not age-appropriate:

  • baseline FSH levels > cut-off [1] and/or
  • age-specific AMH < cut-off [2] and/or
  • AFC < 5; and/or
• cancellation of a PMA cycle because of poor response (<3 follicles) to high-dose gonadotrophins (250 U/die) and/or
• retrieval of < 4 oocytes in response to high-dose stimulation protocols (3000 U of gonadotrophins).

Exclusion Criteria:

• patients with POI-related conditions, such as ovarian surgery or previous chemo- or radio-therapy; endometriosis or known autoimmune or metabolic diseases.

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort
Sporadic POI; Idiopathic, sporadic POI Caucasian cases. The inclusion criteria will be: age at diagnosis <38 years;; a normal 46,XX karyotype (no FRM1 premutation);; at least one marker of ovarian reserve not age-appropriate:baseline FSH levels > cut-off [1] and/orage-specific AMH < cut-off [2] and/orAFC < 5; and/or; cancellation of a PMA cycle because of poor response (<3 follicles) to high-dose gonadotrophins (250 U/die) and/or; retrieval of < 4 oocytes in response to high-dose stimulation protocols (3000 U of gonadotrophins).
Familial POI; Familial POI cases and not-affected members of pedigrees.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Identification of putative POI-related genes.	Genomic imbalances (<5 Mb in size: copy number variations (CNVs) as micro-deletions and micro-duplications) will be detected in sporadic idiopathic POI patients with the purpose to clarify the role of CNVs in POI pathogenesis and to better unveil both novel candidate genes and pathogenic mechanisms	Year 1-20
Identification of genetic variants co-segregated with phenotype.	Novel genetic variants not previously anticipated will be found: given the variants co-segregate with phenotype, whole-exome sequencing approach in consanguineous and POI pedigrees will identify the causative gene and variants that cause the phenotype.	Year 1-20
To combine array-CGH and WES data mining.	The cumulative effect of different genes/variants will be considered in support of the polygenicity of POI and its heterogeneous phenotype (primarily, the sporadic and familial ones).	Year 1-20

Collaborators and Investigators

• Sponsor: Ospedale Policlinico San Martino
• Investigators: Principal Investigator: Paola Scaruffi, Ospedale San Martino; Study Director: Paola Anserini, Ospedale San Martino

Study record dates

Study Major Dates

• Study Start: January 31, 2012
• Primary Completion (Anticipated): December 31, 2030
• Study Completion (Anticipated): December 31, 2030

Study Registration Dates

• First Submitted: March 17, 2022
• First Submitted That Met QC Criteria: April 6, 2022
• First Posted (Actual): April 14, 2022

Study Record Updates

• Last Update Posted (Actual): April 25, 2022
• Last Update Submitted That Met QC Criteria: April 22, 2022
• Last Verified: April 1, 2022

More Information

Terms related to this study

• Keywords: Premature ovarian failure; NGS; array-CGH
• Additional Relevant MeSH Terms: Endocrine System Diseases; Ovarian Diseases; Adnexal Diseases; Gonadal Disorders; Primary Ovarian Insufficiency; Menopause, Premature
• Other Study ID Numbers: POI genome

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No